Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
Zacks.com on MSN3d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis StudyNew late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Shares of Zenas BioPharma (NASDAQ:ZBIO) rose on Thursday after Wedbush launched the newly IPO’ed biotech's coverage with an ...
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
72.3% of AChR+ patients on Uplizna saw a ≥3-point MG-ADL score improvement vs. 45.2% on placebo. Uplizna is under FDA priority review for IgG4-related disease with a PDUFA date of April 3.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback